B. Ellis

A 5‐week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long‐acting glucagon‐like peptide‐1 analogue, in patients with type 2 diabetes

T. Hardy, F. Tibaldi, J. Chien, 2011, Diabetes, obesity & metabolism.

Engineered FcRn Binding Fusion Peptides Significantly Enhance the Half-Life of a Fab Domain in Cynomolgus Monkeys.

A. Datta-Mannan, D. Witcher, Lihua Huang, 2018, Biotechnology journal.

Engineering and characterization of the long‐acting glucagon‐like peptide‐1 analogue LY2189265, an Fc fusion protein

N. Porksen, G. Etgen, K. Bokvist, 2010, Diabetes/metabolism research and reviews.

LY2189265, a long‐acting glucagon‐like peptide‐1 analogue, showed a dose‐dependent effect on insulin secretion in healthy subjects

F. Tibaldi, J. Chien, P. Barrington, 2011, Diabetes, obesity & metabolism.

Disposition of Basal Insulin Peglispro Compared with 20-kDa Polyethylene Glycol in Rats Following a Single Intravenous or Subcutaneous Dose

V. Wroblewski, B. Ellis, M. Knadler, 2015, Drug Metabolism and Disposition.

Generation and Activity of a Humanized Monoclonal Antibody That Selectively Neutralizes the Epidermal Growth Factor Receptor Ligands Transforming Growth Factor-α and Epiregulin

S. Harlan, M. Breyer, A. Datta-Mannan, 2014, The Journal of Pharmacology and Experimental Therapeutics.

Generation and Activity of a Humanized Monoclonal Antibody that Selectively Neutralizes the Epidermal Growth Factor Receptor Ligands TGF-alpha and Epiregulin

M. Breyer, A. Datta-Mannan, E. Conner, 2014 .

Influence of FcRn binding properties on the gastrointestinal absorption and exposure profile of Fc molecules.

A. Datta-Mannan, B. Ellis, Selina Estwick, 2020, Bioorganic & medicinal chemistry.